Agilent Technologies Inc vs Datadog Inc — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Datadog Inc trades at $247.1 (market cap $93.64B). The key difference: Datadog Inc is far larger — about 2.2× Agilent Technologies Inc's market cap, and Agilent Technologies Inc pays a 0.69% dividend while Datadog Inc pays none. Which is the better fit depends on your goals.
| A | DDOG | |
|---|---|---|
Market Cap | $42.00B | $93.64B |
Sector | Health | Technology |
52-Week High | $157.20 | $288.15 |
52-Week Low | $110.24 | $102.62 |
Enterprise Value | $43.55B | $89.93B |
Dividend Yield | 0.69% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
Datadog (DDOG) trades at $233.93, up 2.02% today, but remains bearish technically with resistance near $244. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.65 versus $0.583 expected, and raised full-year revenue guidance to $4.45B-$4.47B. However, the stock faces pressure from high valuations, with a P/E of 467.86, and concerns over decelerating bookings growth from a major AI customer.
Outlook is mixed: robust revenue growth and AI momentum support long-term potential, but premium valuation and near-term usage volatility pose risks. Analyst consensus is bullish with an $288.55 price target, though insider selling and technical weakness suggest cautious near-term sentiment. Investors should balance growth prospects against execution risks and market expectations.
Trailing returns across standard periods
Latest headlines on both assets
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →